Archives of Dermatological Research

, Volume 297, Issue 3, pp 134–138 | Cite as

The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria

  • Seiko Sanada
  • Toshihiko Tanaka
  • Yoshikazu Kameyoshi
  • Michihiro Hide
Short Communication

Abstract

Many patients with chronic idiopathic urticaria are not sufficiently controlled with histamine H1-receptor antagonists. Leukotriene receptor antagonists have been reported to be effective for certain cases of urticaria, although their proper application remains to be established. To study the effectiveness of montelukast, a leukotriene receptor antagonist, for the treatment of chronic urticaria that was not controlled by histamine H1-receptor antagonists. Twenty-five patients with chronic idiopathic urticaria were treated with 10 mg of montelukast for one week or more, without changing any precedent treatment that they were using before the study including histamine H1-receptor antagonists. The effectiveness of montelukast for each patient was evaluated and compared with clinical features and/or backgrounds of the patients. Twelve patients, including six who had been treated with corticosteroids, were evaluated as “markedly improved” or “improved” following treatment with montelukast. There was no statistically significant relation of the effectiveness to the complications with non-steroidal anti-inflammatory drugs (NSAIDs) intolerance, mechanical urticaria, or reactions to autologous serum skin test. However, the patients for whom montelukast was effective were younger (33.2±16.3 years, mean ± SD)(P<0.05, Mann-Whitney test) and their duration of illness shorter (15.9±18.3 months) (P<0.005, Mann-Whitney test) than those of patients for whom montelukast was ineffective (45.9±15.0 years, 89.6±71.7 months). Montelukast may be worth trying for patients with chronic idiopathic urticaria, when the condition is not sufficiently controlled with histamine H1-receptor antagonists.

Keywords

Chronic urticaria Histamine H1-receptor antagonist Leukotriene receptor antagonist Age Treatment 

References

  1. 1.
    Bagenstose SE, Levin L, Bernstein JA (2004) The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 113:134–140CrossRefPubMedGoogle Scholar
  2. 2.
    Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CTC, Hindley F, Marks R, Hazell M, Rowell NR, Fairiss GM, Cartwright PH, Glenny HP, Howland K (1987) Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 117:81–88PubMedCrossRefGoogle Scholar
  3. 3.
    Cook LJ, Shuster S (1983) Lack of effect of cimetidine in chronic-idiopathic urticaria. Acta Dermatovener 63:265–267Google Scholar
  4. 4.
    Di Lorenzo G, Pacor ML, Mansueto P, Pellitteri ME, Bianco CL, Ditta V (2004) Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 114:619–625CrossRefPubMedGoogle Scholar
  5. 5.
    Grattan CE, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, Kobza Black A, Greaves MW (2000) Randomized double-blind study of cyclosporin in chronic ’idiopathic’ urticaria. Br J Dermatol 143:365–372CrossRefPubMedGoogle Scholar
  6. 6.
    Grattan CE, Sabroe RA, Greaves MW (2002) Chronic urticaria. J Am Acad Dermatol 46:645–657CrossRefPubMedGoogle Scholar
  7. 7.
    Kaplan AP (2002) Chronic urticaria and angioedema. N Engl J Med 346:175–179CrossRefPubMedGoogle Scholar
  8. 8.
    National Institutes of Health NHLBI (2005) A six-part asthma management program (2002) In: Global strategy for asthma management and prevention. NIH Publication,:93–148. Available form; http://www.ginasthma.com/download.asp?intId=96 (accessed 27 June 2005)
  9. 9.
    Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A (2003) Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 112:212–213PubMedCrossRefGoogle Scholar
  10. 10.
    Ohnishi-Inoue Y, Mituya K, Horio T (1998) Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist. Br J Dermatol 138:483–483CrossRefPubMedGoogle Scholar
  11. 11.
    Pacor ML, Di Lorenzo G, Corrocher R (2001) Efficacy of leukotriene receptor antagonist in chronic urticarikaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 31:1607–1614CrossRefPubMedGoogle Scholar
  12. 12.
    Soter NA, Kaplan AP (2003) Urticaria and Angioedema. In: Freedbarg IM, Eisen AZ, Wolf K, Austen KF, Goldsmith LA, Katz SI (eds) Fitzpatrick’s dermatology in general medicine, 6th ed. McGraw-Hill, New York, pp 1129–1139Google Scholar
  13. 13.
    Soter NA, Lewis RA, Corey EJ, Austen KF (1983) Local effects of synthetic leukotrienes (LTC4.LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol 80:115–119CrossRefPubMedGoogle Scholar
  14. 14.
    Szczeklik A, Stevenson DD (2003) Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111:913–921CrossRefPubMedGoogle Scholar
  15. 15.
    Tedeschi A, Airaghi L, Lorini M, Asero R (2003) Chronic urticaria a role for newer immunomodulatory drugs? Am J Clin Dermatol 4:297–305PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Seiko Sanada
    • 1
  • Toshihiko Tanaka
    • 1
  • Yoshikazu Kameyoshi
    • 1
  • Michihiro Hide
    • 1
  1. 1.Department of Dermatology, Programs for Biomedical Research, Division of Molecular Medical Science, Graduate School of Biomedical SciencesHiroshima UniversityMinami-ku, HiroshimaJapan

Personalised recommendations